Serum level of a soluble receptor for interleukin-2 as a prognostic factor in patients with gastric cancer
- PMID: 10202282
- DOI: 10.1159/000011973
Serum level of a soluble receptor for interleukin-2 as a prognostic factor in patients with gastric cancer
Abstract
Increased levels of a soluble receptor for interleukin-2 (sIL-2R) have been found in the serum from patients with a variety of malignancies. Levels of sIL-2R have not previously been examined in a large group of patients with gastric cancer as a possible indicator of prognosis. Serum levels of sIL-2R were measured preoperatively by an enzyme-linked immunosorbent assay in 121 patients with gastric cancer. The preoperative levels of sIL-2R in patients with gastric cancer were significantly higher than those in normal controls. An elevated level of sIL-2R was significantly correlated with certain clinicopathologic features, which included depth of invasion, lymph node metastasis, lymphatic vessel invasion, blood vessel invasion and clinical stage. The postoperative survival time of patients with elevated levels of sIL-2R was significantly shorter than that of patients with normal levels. Furthermore, a multivariate analysis using Cox's proportional hazards model showed that the combination of levels of carcinoembryonic antigen and sIL-2R was an independent indicator of prognosis. Thus, the serum level of sIL-2R might be a useful prognostic indicator in patients with gastric cancer.
Similar articles
-
Serum-soluble interleukin-2 receptor concentrations in patients with gastric cancer.Cancer. 1994 Nov 15;74(10):2745-8. doi: 10.1002/1097-0142(19941115)74:10<2745::aid-cncr2820741002>3.0.co;2-0. Cancer. 1994. PMID: 7525035
-
Serum soluble interleukin-2 receptor level as a prognostic indicator in gastric cancer.Br J Cancer. 1998 Jun;77(11):1820-4. doi: 10.1038/bjc.1998.302. Br J Cancer. 1998. PMID: 9667652 Free PMC article.
-
Serum soluble interleukin-2 receptor as a predictor of lymph node metastasis in early gastric cancer.Dig Surg. 2002;19(1):9-13; discussion 14. doi: 10.1159/000051999. Dig Surg. 2002. PMID: 11961349
-
The soluble interleukin-2 receptor: biology, function, and clinical application.Ann Intern Med. 1990 Oct 15;113(8):619-27. doi: 10.7326/0003-4819-113-8-619. Ann Intern Med. 1990. PMID: 2205142 Review.
-
Soluble interleukin-2 receptor in cancer.Front Biosci. 2004 Sep 1;9:3085-90. doi: 10.2741/1461. Front Biosci. 2004. PMID: 15353339 Review.
Cited by
-
Lymphocyte subsets and T(h)1/T(h)2 immune responses in patients with adenocarcinoma of the oesophagus or oesophagogastric junction: relation to pTNM stage and clinical outcome.Cancer Immunol Immunother. 2003 Oct;52(10):617-24. doi: 10.1007/s00262-003-0406-7. Epub 2003 Jun 12. Cancer Immunol Immunother. 2003. PMID: 12802519 Free PMC article.
-
Mutations and regulatory anomalies effecting tumor cell immune functions.Cancer Immunol Immunother. 2004 Jan;53(1):1-16. doi: 10.1007/s00262-003-0418-3. Epub 2003 Sep 12. Cancer Immunol Immunother. 2004. PMID: 13680191 Free PMC article. Review.
-
Biomarkers of Helicobacter pylori-associated gastric cancer.Gut Microbes. 2013 Nov-Dec;4(6):532-40. doi: 10.4161/gmic.25720. Epub 2013 Jul 12. Gut Microbes. 2013. PMID: 23851317 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical